Articles by Bethan Warman

Dr Ranjit Manchanda awarded William Blair Bell Memorial Lecture

9th March 2018

Congratulations to our Dr Ranjit Manchanda, Centre for Experimental Cancer Medicine, who has been awarded the William Blair Bell Memorial Lecture prize. Dr Ranjit Manchanda was awarded with the prize on 8th February and presented his lecture, entitled ‘Population based germline testing and targeted ovarian cancer prevention,’ the following day.

Read more

Switching on survival signalling to drive drug resistance

27th February 2018

Researchers at the Barts Cancer Institute (BCI), Queen Mary University of London, led by Dr Richard Grose, Centre for Tumour Biology, have discovered that the loss of a single protein- PHLDA1- is sufficient for the development of drug resistance to a type of targeted therapy in endometrial and HER2-positive breast cancer cells.

Read more

The involvement of the microenvironment in tumour evolution

15th February 2018

For the first time, researchers at the Barts Cancer Institute (BCI), Queen Mary University of London, have profiled what happens at the site of tumour metastasis as cancer grows and develops. By looking closely at the tumour microenvironment (TME), the team led by Professor Fran Balkwill, Lead for the Centre for Cancer & Inflammation, has identified changes that occur as a type of ovarian cancer evolves.

Read more

Staying connected: New developments for tissue banking bioinformatics

1st February 2018

A team of researchers at the Barts Cancer Institute (BCI) of Queen Mary University of London have developed new analytical tools to aid in the analysis of tissue bank (TB) samples, which are an extremely valuable resource for scientists.

Read more

Researchers use flu-like virus to attack pancreatic cancer

25th January 2018

A flu-like virus has now been used in experiments to successfully inhibit the growth of pancreatic cancer, according to an early study by researchers at the Barts Cancer Institute (BCI) of Queen Mary University of London (QMUL).

Read more

Steps towards the development of a new immunotherapy for pancreatic cancer

23rd January 2018

A research team led by Professor Yaohe Wang at the Barts Cancer Institute (BCI) of Queen Mary University of London (QMUL) has created a novel oncolytic viral agent expressing interleukin-12 (IL-12) that shows promise as a potential anti-tumour immunotherapy for the treatment of pancreatic cancer.

Read more

Search News
Categories
Archives
Tags